FWIW I think CYDY likely has what it needs at 28 d
Post# of 148169
IMO Nader's decision to not do the 75% review & to not add the 42 days observation to the official protocol (to the best of my knowledge) also may have been strategic in a way I haven't seen mentioned. He may have realized that by NOT extending the observation period, he gives other drugs some limited ability to compare to a SOC without Leronlimab in s/c cases.
Part of me thinks this plays politics a little, but results in changing more hearts & minds at the FDA which leads to more respect with other trials.
JMO